Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Role of Dopamine Receptors in Primary Focal Dystonias

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified August 2011 by Washington University School of Medicine
Sponsor:
Collaborator:
Information provided by:
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT01373840
First received: June 10, 2011
Last updated: August 2, 2011
Last verified: August 2011
  Purpose

Dystonia is a disabling movement disorder characterized by repetitive patterned or sustained muscle contractions causing twisting or abnormal postures that may afflict 250,000 people in the U.S. While the pathophysiology of dystonia remains uncertain the treatment is rather rudimentary. A better understanding of neural mechanisms of dystonias is not only an invaluable prerequisite for developing better treatment options but also a step toward better understanding of the complex network of basal ganglia. In this study I will investigate if there is any difference between the dopamine receptors and dopamine in people with dystonia and healthy subjects.


Condition
Healthy
Focal Dystonias

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Role of Dopamine Receptors in Primary Focal Dystonias

Resource links provided by NLM:


Further study details as provided by Washington University School of Medicine:

Estimated Enrollment: 40
Study Start Date: September 2011
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts
healthy controls
patients with focal dystonias

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Any healthy control or patient with primary focal dystonia or arm or face.

Criteria

Inclusion Criteria:

  • Age >20
  • Male or Female
  • Any race or ethnicity
  • Primary focal dystonia (arm or cranial)
  • Ability to give informed consent

Exclusion criteria:

  • Family history of dystonia
  • Pregnancy (confirmed with negative urine pregnancy test in women of child bearing potential), breastfeeding
  • Exposure to radiation therapy
  • Any MRI contraindications such as foreign metallic implants, pacemaker, and aneurysm clip etc.
  • History of cardiac disease, uncontrolled hypertension, abnormal EKG during screening phase
  • History of exposure to any drugs affecting dopaminergic systems within the last 6 months (e.g. dopamine receptor blocking agents, cocaine, amphetamine, tetrabenazine, reserpine, L-dopa, dopamine agonists, as they might affect the dopamine receptor binding or endogenous dopamine).
  • Active depression (Beck Depression Inventory_II >14)
  • Cognitive impairment (Mini-Mental State Score <27)
  • CNS active medications such as gabapentin or narcotics, muscle relaxants which might be given for pain in the 3 days prior to study
  • History of stroke, seizure, cerebral palsy, generalized dystonia, parkinsonism, inability to hold head still during the scanning time.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01373840

Contacts
Contact: Pratt Stacey 314-747-5916 pratts@npg.wustl.edu

Locations
United States, Missouri
Washington University Not yet recruiting
St. Louis, Missouri, United States, 63141
Contact: Stacey Pratt    314-747-5916    pratts@npg.wustl.edu   
Principal Investigator: Morvarid Karimi, MD         
Sponsors and Collaborators
Washington University School of Medicine
Investigators
Principal Investigator: Morvarid Karimi, MD Washington University School of Medicine
  More Information

No publications provided

Responsible Party: Morvarid Karimi, MD, Washington University
ClinicalTrials.gov Identifier: NCT01373840     History of Changes
Other Study ID Numbers: 201102481
Study First Received: June 10, 2011
Last Updated: August 2, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Washington University School of Medicine:
focal
dystonia
dopamine
receptor

Additional relevant MeSH terms:
Dystonia
Dystonic Disorders
Central Nervous System Diseases
Dyskinesias
Movement Disorders
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Dopamine
Dopamine Agents
Autonomic Agents
Cardiotonic Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Sympathomimetics
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014